James Mackay, Aristea Therapeutics president and CEO
February 10, 2023 10:03 AM EST
People
R&D

Aris­tea shut­ters, end­ing hopes of a Pfiz­er buy­out

Kyle LaHucik

Senior Reporter

As­traZeneca spin­out Aris­tea Ther­a­peu­tics is shut­ting down af­ter ter­mi­nat­ing mul­ti­ple Phase II stud­ies of its in­flam­ma­to­ry drug, cit­ing undis­closed safe­ty is­sues …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times